INTRODUCTION INTRODUCTION
factors: strain, dose and schedule of BCG vaccination; genetic and physiologic characteristics of the population; environmental The protective effect of bacillus Calmette Guérin (BCG) vaccine mycobacteria and form of disease within the spectrum of in mycobacterial diseases has been a matter of long-standing controversy. Although the BCG vaccine has been rationalized for use in tuberculosis, its role in the prevention of leprosy was hypothesized as early as 1939. [1] These observations were later confirmed by several researchers [1] [2] [3] and led to a series of studies to evaluate the protective efficacy of BCG against leprosy. The range of protection observed in these studies was very wide, i.e., 20-90%. [8, [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] The variation in protective effect has been attributed to several leprosy. Moreover, different study designs, varying inclusion and exclusion criteria and different statistical estimators of the strength of association can all contribute to the variation in the estimated protective effect. As a consequence, summarization of the protective effect becomes difficult.
As meta-analysis systematically combines the results from different studies, we undertook to summarize the protective effect of BCG vaccine in prevention of leprosy using meta analytic procedures. Zodpey SP: Protective effect of BCG vaccine in the prevention of leprosy
METHODS METHODS

Identification of studies
A computerized literature search using the MEDLINE ® database was conducted. The following key words were used for searching: BCG, efficacy or effectiveness, protective effect and leprosy. The search was not limited to articles in the English language. Snowballing technique was then used to identify and locate potential studies by scanning the references of all the retrieved articles. Previously compiled efficacy/effectiveness for an overall review. However for the purpose of meta-analysis, raw data (in the form of 2x2 tables) from each study was used as input data. When original studies did not report information in 2x2 tables, it was constructed using other available information in the study. This was necessary as the software [36] which was used for meta-analysis required information in the form of 2x2 tables as input data. Hence for a few studies, there is variation in estimates of OR/RR reported in original studies and calculated by MetaAnalyst software. [36] lists of BCG studies and articles providing an overview of these studies were reviewed and experts on BCG vaccination
Statistical analysis
were contacted. Manual search was also carried out to search
The results are presented as relative risks (RRs) from the for articles in non-indexed journals.
trials and cohort studies and as odds ratios (OR) from the case-control studies. The protective effect was also
Inclusion and exclusion criteria
presented, as defined as 1-RR or 1-OR. The random effects Only studies measuring the efficacy or effectiveness of model as described by DerSimonian and Laird [37] was used to BCG vaccination in preventing leprosy were included in summarize the effect measures. This model was separately the present meta-analysis. It included case-control studies, applied to trials, cohort studies and case-control studies. For cohort studies as well as randomized control trials. Other each summarization, a chi-square test of heterogeneity was observational studies (outbreak investigation, household estimated. The analysis was performed using Meta-Analyst contact study, surveillance study, case-series and incidence software (Version 0.99 x; 1998). [36] trends analysis) were also reviewed; however, these studies were not subjected to meta-analysis. Studies of leprosy
Review of studies
prevalence, investigations of leprosy control programs and Although 29 studies were retrieved, which reported a reviews of leprosy vaccination studies were searched for protective effect of BCG in prevention of leprosy; meta relevant references but were not included in the analysis. analysis could only include 22 studies, which satisfied the The studies that considered results of lepromin reaction inclusion criteria. To strengthen the viewpoint further, the as the outcome were excluded. Multiple reports of a single additional information from the studies not included in meta study were reviewed when they were available to obtain analysis, was also utilized separately. the most complete information possible. However, multiple reports did not amount to duplication of information; they RESULT TS RESUL were considered together as one single study. In case of several consecutive reports of the same study, the latest Twenty-nine studies of the protective effect of the BCG one was used for data extraction. By following these vaccine against leprosy were reported in literature. These inclusion and exclusion criteria, the present meta-analysis studies were carried out by different investigators in different finally included 22 studies on the role of BCG vaccine in regions of the world and using different study designs [ 
Data extraction
The following information was extracted from each study: design of the study, authors, year of publication, number of participants enrolled (along with their exposure and disease status), location of study, population group and reported estimates of effect measures-relative risks / odds ratios (RR/ OR) or vaccine effectiveness/ efficacy and their 95% confidence intervals (CI). When studies analyzed data using adjustments for a combination of variables (for example, using logistic regression or Poisson regression or Cox proportional hazards regression etc.), we recorded reported estimates of vaccine 1]. Variation in the efficacy/effectiveness of BCG vaccine is evident from the results of these studies. The point estimates of protective effect obtained ranged from 18-90%.
When the results of an individual study were analyzed for significance of a protective effect (based on the point estimates and 95% CI), it was evident that five of 23 studies (six studies [10] [11] [12] [13] [14] 26] were not included for this analysis of significance as they did not report either point estimates or 95% CI) did not demonstrate any significant protective effect of BCG vaccination in the prevention of leprosy. Thus 18 (78.3%) studies recognized a significant protective association between BCG vaccination and leprosy. Further analysis of these 29 studies according to the level demonstrated protection ranging from 26-96%. The point of protection, revealed that not a single study reported a estimates for efficacy were not available for these studies negative protective effect (point estimates for RR or OR > 1). and these early trials had several weaknesses and biases, A total of 16 (55.2%) studies exhibited less than 50% efficacy/ particularly with regard to the comparability between BCG effectiveness. However, about 12 (75%) of these 16 studies vaccinated and control groups. The range of protective effect reported a protective effect in the range of 25-49%. Thirteen (point estimates) observed in these trials was very wide, from (44.8%) studies demonstrated ≥ 50% efficacy/effectiveness. The same kind of analysis was also carried out by excluding five early trials, [10] [11] [12] [13] [14] which did not report point estimates but reported only the range of protection and had a major methodological limitation because of lack of comparability. After exclusion, studies that reported < 50% protective effects were brought down to 45.8%. A total of 13 (54.2%) studies demonstrated efficacy/effectiveness > 50%. Five (20.9%) studies reported ≥ 75% protection against leprosy. Table 1 describes the observed protective effect of BCG vaccines against leprosy as estimated in eight trials. [4,5,9,15 21,26] This table also includes the five early trials in Brazil, [10] Argentina,
[11] Venezuela, [12] India [13] and Japan, [14] which 18-80% [ Table 1 ].
Of the above-described eight trials, six trials meeting the inclusion and exclusion criteria were subjected to meta analysis using random effects model [ Table 2 ]. Venezuela trial, [26] which compared a BCG alone group with BCG + M. leprae group, was not included for meta-analysis because there was no comparison between the BCG-immunized and BCG-unimmunized groups in this trial. Additionally, the Northern Malawi trial (by Karonga Prevention Trial Group), [5] which evaluated the protective effect of 'repeat BCG' in the prevention of tuberculosis was also not subjected to meta analysis. Zodpey SP: Protective effect of BCG vaccine in the prevention of leprosy One study [19] reported a prospective trial of anti-leprosy vaccines in 893 household contacts of leprosy patients. Of these, 179 contacts were vaccinated using three different vaccine interventions, namely: killed M. leprae (n=85), BCG (n=46) and a mixture of M. leprae and BCG (n=48). While the study reported 14 new cases in the vaccine group within an eight year followup period, the distribution of these 14 leprosy cases among the three vaccine groups was not reported. The study, however, observed identical lepromin conversion rates across the three vaccine groups. Therefore, we included this study in the current meta-analysis with 179 and 714 subjects in the intervention and non-intervention groups, respectively. However, meta-analysis was also performed separately by excluding this study. Table 2 describes the results of meta-analysis of trials using random effects model by including and excluding the study by Chaudhury. [19] By combining five trials, a summary relative risk of 0.57 (0.44-0.74) was estimated, which confirmed the significant protective association of BCG vaccination with leprosy. Addition of data from a sixth trial (as an independent and individual study) narrowed down the 95% CI slightly but the point estimate of 0.57 remained unaffected. These studies also demonstrated significant heterogeneity.
Two cohort studies [6, 7, 22] of BCG vaccination and leprosy were retrieved from literature. Table 1 shows the information extracted from these two studies. For one study, [ reports were available for which the group with a doubtful BCG scar was merged with the BCG-negative group for calculating RR. This was necessary as the split-up information was not available for these groups. The two studies included in Table 1 reported moderate protective effect (57 and 54%) of BCG vaccination in the prevention of leprosy. Meta-analysis included these studies to estimate a summary protective effect using random effects model [ Table 2 ]. The DerSimonian and Laird random effects model estimated a weighted average RR of 0.38 (0.31-0.47) from the data of two cohort Table 3 summarizes the results of meta-analysis by study design. It is evident from the table that the summary RR from the cohort studies was lower than the summary OR from case-control studies and summary RR from trials. However, these differences were not statistically significant as suggested by overlapping 95% CI. The summary protective effects calculated from trials, cohort studies and casecontrol studies were 43 (27-55), 62 (53-69) and 58 (47-67)% respectively, which were statistically significant. These estimates confirmed the protective association between BCG studies corresponding to a protective effect of 62% (53) (54) (55) (56) (57) (58) (59) (60) (61) (62) (63) (64) (65) (66) (67) (68) (69) vaccination with leprosy. Except cohort studies, the other two against leprosy. The point estimate of protective effect was groups exhibited significant heterogeneity. statistically significant as reflected by 95% CI. These studies did not report significant heterogeneity.
DISCUSSION DISCUSSION
A total of 14 case-control studies of BCG vaccination and The story of vaccines against leprosy is unusual for its irony. leprosy were reported in literature. Table 1 states the Although some claim that there is no anti-leprosy vaccine, [38] effectiveness, publishing authors, year of publication and more people alive today have received an anti-leprosy vaccine study area for these studies. For one of these studies, multiple than have received any other vaccine. In fact, more than 100 reports were available. The range of protection observed in million infants and children received it in 1995. The vaccine these studies was very wide, i.e., 20-90%. All the 14 retrieved is BCG and the irony arises because the vaccine is so widely case-control studies were included in meta-analysis [Table  directed against tuberculosis that many have forgotten its 2]. Combining the data from 14 case-control studies, a important implications for leprosy.
[39]
summary odds ratio (OR) of 0.42 (0.33-0.53) was estimated, which confirmed the significant protective association of BCG was the first vaccine to be considered against leprosy BCG vaccination with leprosy. These studies also exhibited following the report of Fernandez in 1939 on lepromin significant heterogeneity.
conversion among lepromin-negative healthy children following BCG administration.
[40] The next 20 years witnessed There was a slight variation in the estimates of OR (and a number of small-scale studies in selected populations, thus vaccine effectiveness) reported in the original studies which suggested the value of BCG vaccine in the prevention of and obtained from the meta-analysis for a few case-control leprosy. [1, 17] A few early studies with methodologic limitations, studies. Original studies reported OR based on different types demonstrated protection ranging from 26-96%. [10] [11] [12] [13] [14] Later in of analysis i.e., matched, adjusted, stratified etc. However, for 1965, Shepard provided the first experimental evidence in the purpose of meta-analysis using Meta-Analyst Software, favor of BCG in the mouse footpad model. [1] During the same the raw data (unmatched data from 2x2 tables) was used as decade, four major field trials were initiated in Uganda, [15] input information as this was the requirement of statistical India, [2, 4, 20] Burma [17] and Papua New Guinea [9, 18] to evaluate the software. Therefore meta-analysis reported unmatched crude efficacy of BCG vaccine in the prevention of leprosy, which estimates of OR.
was followed by a few more trials. The results of these trials Zodpey SP: Protective effect of BCG vaccine in the prevention of leprosy showed wide variation in the protective effect of BCG vaccine, ranging from 20-80%. [4, 9, [15] [16] [17] [18] [19] [20] [21] 41] A couple of cohort studies, which were carried out in Northern Malawi, exhibited 57 and 54% protective efficacy of the BCG vaccine.
[6,7,22] Since P. G. Smith recommended the use of case-control studies for assessing vaccine effectiveness, a total of thirteen casecontrol studies of BCG vaccine effectiveness against leprosy were reported in literature. [8, [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] 42] The range of protection observed in these studies was also very wide, i.e., 20 90%. [8, [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] 42] Thus, the variations of efficacy against leprosy others, for example, Eastern Africa. [15, 43] The implications of these two facts are simple-BCG must be having an impact on leprosy worldwide and is undoubtedly responsible, at least in part, for the decline in leprosy incidence observed in many populations. It is probably not a coincidence that the highest protective efficacy estimates for BCG against leprosy have come from studies in Africa (80% in Uganda) [15] and that some of the greatest recent decreases in incidence of leprosy have also been reported from that continent. [45] are reminiscent of variations observed of the effect of BCG While appreciating the role of BCG in leprosy prevention against tuberculosis. [43] today, one should not neglect its idiosyncrasies, in particular, the fact that its effects differ between populations for In order to estimate the summary protective effect of reasons not understood so far. [43, 47] It is unfortunate that BCG vaccine in prevention of leprosy, the meta-analysis of the effectiveness of BCG appears to be less in India than in published studies of BCG vaccination and leprosy was carried Africa, given that there is much more leprosy in India than out against this background. The summary protective effects in Africa. And what about Brazil? Why is leprosy apparently calculated from trials, cohort studies and case-control studies increasing there in spite of socioeconomic improvement as were 43 (27-55), 62 (53-69) and 59 (46-68)% respectively, well as widespread use of BCG? [45] which were statistically significant and hence confirmed the protective association between BCG vaccination and leprosy.
What is particularly important is that as far as available data Thus, the findings of the current meta-analysis recognized is concerned, BCG vaccine is at least as effective in preventing a significant protective effect of BCG vaccination in the leprosy as it is in preventing tuberculosis. In addition, the only prevention of leprosy.
three studies in which the activity of the same BCG vaccine in preventing leprosy and tuberculosis has been studied in To substantiate the findings of current research work, 28 the same populations, have actually demonstrated that the studies of BCG vaccination and leprosy were also reviewed.
BCG vaccine is more effective against leprosy than against None of these studies reported a negative protective effect.
tuberculosis [54% vs 11% in Malawi; [48] 81% vs 22% in Kenya [8] Moreover, of the 22 studies (which reported significance and 22% vs -5% in South India]. [4, 16, 20, [49] [50] [51] [52] either using 95% CI or P values), 17 (77.3%) studies had recognized a significant protective association between BCG This has important practical implications as well as vaccination and leprosy. A total of 12 (52%) studies out of 23 implications for research. In practice, it means that at demonstrated a protective effect > 50%. Five (21.8%) studies this moment, there is in progress a massive anti-leprosy reported > 75% protection against leprosy. This is certainly vaccination program, which is undoubtedly playing an cumulative global evidence in favor of use of BCG vaccine for important role in the worldwide reduction of the incidence of prevention of leprosy.
leprosy. One should not therefore forget that when we talk of the low protective effect of BCG vaccine against tuberculosis, Few investigators went a step ahead to generalize the protective effect and stated that the BCG has had a demonstrable impact on the prevalence of leprosy despite variable results with BCG in formal studies.
[44] Fine reviewed the reasons for declining trends of leprosy incidence throughout the world. [45, 46] Fine states that the leprosy community has long been schizophrenic on the subject of BCG.
[45] The facts are simple. First, more people have received BCG than have received any other vaccine-till 1992 over two billion doses have been administered. Second, wherever it has been studied, it has been found that BCG imparts some protection against leprosy. The protection appears to be relatively modest in some contexts, for example Burma, [17] but quite high in we also should take into account its role against leprosy. This is the additional advantage that we are gaining out of mass neonatal BCG vaccination programs. As we understand, although the BCG vaccination has not been an official or a formal component of Leprosy Control Programs anywhere in the world, it is still contributing to leprosy control. Secondly, the relationship between the actions of BCG in leprosy and in tuberculosis may provide a clue to the very important questions of protective immunity and correlates of protection against tuberculosis as well as leprosy.
[10]
It is not surprising that while the BCG vaccine is being used for the prevention of tuberculosis, it is also preventing Zodpey SP: Protective effect of BCG vaccine in the prevention of leprosy leprosy. The BCG vaccine is basically known to protect against disease caused by Mycobacterium tuberculosis, which has a number of antigens in common with M. leprae. There is convincing experimental and circumstantial evidence that exposure to one species of mycobacteria can provide an individual human host with some degree of protection against infection by another species. [53] BCG vaccination might therefore also protect against disease caused by M. leprae, i.e., leprosy. [9] The rationale of the use of BCG as a preventive vaccine against leprosy also rests on the assumption that The present study suffers from all the limitations that are Despite all the limitations, the present meta-analysis reported significant and stable estimates of protective effects across study designs.
Finally to conclude the discussion of this research, there is sufficient and convincing evidence of the protective effect of BCG vaccine against leprosy, as reflected from the meta analysis of trials, cohort studies and case-control studies and overall review of 29 studies of BCG vaccination and leprosy. This cumulative evidence certainly strengthens the case of the usefulness of the BCG vaccine. In general, the results of the current study and review support arguments favoring the use of the BCG vaccine for the prevention of leprosy. ) .
